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Background: Renal involvement in sickle cell disease (SCD) contributes significantly to morbidity and mortality. The
aim of this study was to determine the prevalence of chronic kidney disease (CKD) amongst SCD patients, and how
basic clinical variables differ across haemoglobin genotypes.
Methods: A hospital-based cross-sectional study conducted from December 2013 to May 2014 at the Sickle cell clinic
of the Tema General Hospital. One hundred and ninety-four (194) participants with SCD, receiving medical care at the
outpatient sickle cell clinic were enrolled onto the study. A structured questionnaire was administered to obtain information
on demography, clinical history, blood pressure and anthropometry. Blood and urine samples were taken for serum
creatinine and proteinuria determination respectively. The estimated GFR (eGFR) was calculated using the CKD-EPI and
Schwartz equations. CKD was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
Analysis was performed using GraphPad prism and P <0.05 was considered statistically significant.
Results: CKD was present in 39.2 % of participants. Using KDIGO guidelines, 40.8 % of the HbSS participants had stage 1
CKD and none had stage 2 CKD. In addition, 30.8 % of the HbSC participants had stage 1 CKD and 3.8 % had stage 2 CKD.
There was a trend of increasing age across CKD stages and stage 2 CKD participants were oldest (P < 0.001).
Conclusion: Results from the current study suggest that CKD is common amongst SCD patients and prevalence and
intensity increases with age. Proteinuria and CKD was more common in HbSS genotype than in HbSC genotype.
Keywords: Chronic kidney disease, Ghana, HbSS, HbSC, Sickle cell diseaseBackground
Sickle cell disease (SCD) is a haemoglobinopathy, which
occurs due to a mutation in the globin gene of haemo-
globin [1]. SCD may occur as a homozygous inheritance
of haemoglobin S (HbSS), heterozygous inheritance of
HbS with other β-globin mutations (e.g. HbSC) or even
quantitative mutations that result in decreased or absent
β-globin synthesis (the thalassaaemias) [1, 2].
Prevalence of SCD worldwide is 2 % in West Africa and
in Ghana [3, 4]. SCD is characterized by red blood cell
sickling, vaso-occlusion, haemolysis, acute anaemia and
high morbidity and mortality and this is common in those* Correspondence: rephraim@ucc.edu.gh
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unless otherwise stated.with homozygous HbSS genotype [5]. These consequences
amongst others, that result from SCD has a broad mani-
festation that affects various organ systems in the body
[6], of which chronic kidney disease (CKD) is a part.
CKD is the presence of kidney damage or decreased kid-
ney function, which is progressive (from three or more
months to years) irrespective of clinical diagnosis [7]. Renal
disease is seen in 15-18 % of all SCD patients, and is a cause
of early death [8, 9]. CKD from sickle cell involves damage
to multiple structures within the kidney [1]. The haemo-
dynamic changes that occur with chronic anaemia, renal
hypoxia that results from recurrent vaso-occlusion and
haemolysis-related endothelial dysfunction can lead to func-
tional and structural changes which may progress to CKD
[8, 10-12].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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program is yet to cover the entire country. Hence, diagno-
sis of SCD in several parts of Ghana is often delayed and
occurs after several visits to the hospital or clinic with
acute illness. This means that organ impairment may set
in long before diagnosis, increasing the risk for develop-
ment of CKD and increased morbidity and mortality [3].
Furthermore, common clinical markers of renal function
such as serum creatinine are not reliable indicators of
early stage glomerulopathy in SCD because of the in-
creased eGFR, lower muscle mass, and increased tubular
secretion of creatinine in individuals with SCD [13, 14].
This matter is of great concern and there is dearth of in-
formation about the renal status of SCD patients in Ghana.
Substantial data on the issue as well as early detection and
treatment amongst this target group will be of great help.
The aim of this study was to determine the prevalence of
CKD amongst a population with SCD and how basic clinical
variables differ across haemoglobin genotypes.
Methods
Study design and site
This was a hospital-based cross-sectional study with
consecutive sampling technique, conducted amongst
SCD patients attending the sickle cell clinic at the Tema
General Hospital (TGH), Tema, Ghana. The study was
conducted from December 2013 to May 2014. TGH
serves as the main referral centre for residents of the
south-eastern parts of Ghana and offers general and spe-
cialist care services.
Study population
One hundred and ninety- four participants were recruited
for the study. A structured questionnaire (Additional file 1)
was administered to each participant via interview, to ob-
tain information on demography and clinical history (con-
firmed and reviewed via patient charts). To be eligible,
participants had to be aged 5 years and above with con-
firmed HbSS or HbSC and in a steady clinical state for at
least two weeks before recruitment. Individuals with sickle
cell trait (HbAS) were not included in the study. Partici-
pants with symptoms suggestive of sickle cell pain crisis,
acute illness (including having a fever or needing referral
to an urgent care centre), clinically suspected urinary tract
infection and gross haematuria were excluded. We ex-
cluded participants who were known to be infected with
HIV or with a systemic condition that could result in a glo-
merulopathy not related to SCA (e.g. active hepatitis B or
C infections, systemic lupus erythematosus).
Ethical consideration
The study was approved by the Institutional Review Board,
University of Cape Coast (IRB/UCC) and the Committee of
Ethics, Tema General Hospital. Participation was voluntaryand written informed consent was obtained from partici-
pants or from parents and guardians of children. Data was
de-identified before analysis.
Blood pressure measurement
Trained personnel measured the blood pressure of partici-
pants (mercury sphygmomanometer and stethoscope) in ac-
cordance with recommendations of the American Heart
Association [15]. Repeated measurements were taken within
5–10 minutes rest interval and the mean value was recorded
as the blood pressure.
Anthropometry
Height (to the nearest 0.1 cm) without shoes was measured
with a wall-mounted ruler (LINDELS, Klippan, Sweden).
Weight (to the nearest 0.1 kg) in light clothing was mea-
sured with a balance (Seca, Hamburg, Deutschland). Body
Mass Index (BMI) was calculated using the formula; weight
(kg)/height (m2). Overall obesity was defined as a BMI of
≥30 kg/m2, normal weight as 18.5–24.9 kg/m2, underweight
as <18.5 kg/m2 and overweight as 25.0–29.9 kg/m2 in adults
[16]. In children however, we defined according to the CDC,
≥95th percentile as obese, 85th-94th percentiles as over-
weight and 5th-84th percentile as normal and <5th percentile
as underweight [17,18].
Blood sample collection and processing
Five millilitres of venous blood was obtained from each
participant into serum gel separator (SST) and Ethylene-
diaminetetraacetic acid (EDTA) anticoagulated tubes,
from which biochemical and haematological assays were
performed respectively. Haematological assays were per-
formed on fresh anticoagulated blood using an auto-
mated analyser (Mindray BC 3000 Plus, Shenzhen,
China). Blood in SST’s were allowed to clot, centrifuged
at 1500 g for 3 minutes, and serum creatinine was esti-
mated using an automated chemistry analyser (Selectra
Junior, Vital Scientific NV, Netherlands).
Urine sample collection and processing
Participants provided early morning urine, collected into a
clean, dry, sterile and wide-necked container. Urine pro-
tein was estimated semi-quantitatively using commercially
available urine test strips (highly sensitive for albumin) as
per manufacturer’s instructions. “Trace” protein is equiva-
lent to 10 mg/100 ml or about 150 mg/24 hours (the
upper limit of normal). 1+ corresponds to about 200–
500 mg/24 hours; 2+ to 0.5-1.5 g/24 hours, a 3+ to 2–5 g/
24 hours, and a 4+ represents 7 g/24 hours or greater.
Outcome criteria
The estimated GFR (eGFR) was calculated for adults using
the chronic kidney disease epidemiology collaboration
(CKD-EPI) equation [19] and the Schwartz equation was
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tion for creatinine used was as follows:
141min Scr=κ; 1ð Þα max Scr=κ; 1ð Þ−1:209
 0:993Age  1:018 if femaleð Þ  1:159 if blackð Þ
where Scr is serum creatinine in mg/dl, k is 0.7 for females
and 0.9 for males, α is −0.329 for females and −0.411 for
males, min indicates the minimum of Scr /κ or 1, and max
indicates the maximum of Scr /κ or 1.
The CKD-EPI equation has recently been suggested as
the best option for the eGFR determination in SCD [22].
The updated Schwartz equation used was as follows:
eGRF ml=min=1:73m2
  ¼ 0:413 height cmð Þ=Serumcreatinine mg=dlð Þ
The calculated eGFR was used to stratify the study
population into stages of CKD, based on the staging sys-
tem of the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines for CKD. The various stages were de-
fined as follows: Stage 1 (Kidney damage with normal or
increased eGFR) = ≥90 ml/min/1.73 m2; Stage 2 (Kidney
damage with mildly decreased eGFR) = 60–89 ml/min/
1.73 m2; Stage 3a (mild to moderately decreased eGFR) =
45–59 ml/min/1.73 m2; Stage 3b (moderate to severely de-
creased eGFR) = 30–44 ml/min/1.73 m2; Stage 4 (severely
decreased eGFR) = 15–29 ml/min/1.73 m2 and Stage 5
(Kidney failure) = <15 ml/min/1.73 m2 [19]. CKD accord-
ing to KDIGO organization is defined as either decreased
estimated glomerular filtration rate (eGFR < 60 mL/min/
1.73 m2 corresponding to stage 3–5) or evidence of kidney
damage (albuminuria, or overt proteinuria [23]. Glomeru-
lar hyperfiltration was defined as eGFR >140 [24, 25].
Statistical Analysis
Values are expressed as mean ± SD or frequencies and pro-
portions. Differences between groups were determined by
unpaired t test, Chi-square, Fisher’s exact test or ANOVA,
where appropriate. A multivariate logistic regression was
performed to determine the factors, which may be associ-
ated with CKD amongst different populations. P <0.05 was
considered statistically significant. Analysis was performed
using GraphPad prism version 5.0 (GraphPad software, San
Diego California USA).
Results
The results of this study showed that 39.2 % of the SCD
participants had CKD. Prevalence of CKD in the paedi-
atric population was 31.6 % and that in the adult popula-
tion was 68.4 %. Glomerular hyperfiltration was present
in 68.8 % of the paediatric population and present in a
lower 31.2 % of the adult population.
Participants with HbSC genotype were older (30 years;
P = 0.001) than the HbSS group (21 years) and there was a
significant difference when the two groups were comparedby age group (P = 0.035). Similarly, the HbSC group had a
higher blood pressure (SBP = 114 mmHg; P = 0.005 and
DBP = 71 mmHg; P = 0.011) and a higher serum creatinine
(55.18 μmol/l; P = 0.004) than their corresponding HbSS
genotype participants. Mean eGFR was however higher in
the participants with HbSS genotype (136 mL/min/
1.73 m2) than in those with HbSC genotype (119 mL/min/
1.73 m2; P = 0.002). HbSC genotype group had a higher
RBC count (3.86 × 106 /mm3; P = 0.000) and HGB con-
centration (14.87 g/dl; P = 0.011) but WBC count was
higher in participants with HbSS genotype (11.83 × 103/
mm3; P = 0.007) (Table 1).
Amongst those with CKD, HbSC participants were older
(P <0.001) and with higher SBP (P= 0.005) and DBP
(P = 0.011) than their HbSS counterparts. Prevalence of
overweight was higher in the HbSC (22.2 %; P = 0.018) par-
ticipants than in the HbSS (0.0 %) participants. Haemato-
logical profile showed that HbSC participants had a higher
RBC count (4.15 × 106 /mm3; P= 0.001) and HGB concen-
tration (10.83 g/dl; P= 0.001), whereas WBC (11.43 × 103/
mm3; P= 0.020) and platelets (348.1 × 103/mm3; P= 0.007)
were higher in HbSS genotype (Table 2).
In Table 3, the prevalence of albuminuria, classifica-
tion by eGFR and stages of CKD is shown according to
SCD genotype. Using KDIGO guidelines, 39.2 % of par-
ticipants had CKD. Based on haemoglobin genotype,
40.8 % of the HbSS participants had stage 1 CKD and
none had stage 2 CKD. In addition, 30.8 % of the HbSC
participants had stage 1 CKD and 3.8 % had stage 2
CKD.
Baseline characteristics are further stratified by CKD
status in Table 4. Participants differed only by age, with
CKD participants older (28 years, P = 0.004) than partici-
pants with no CKD (20 years).
In Table 5, the factors associated with the risk of de-
veloping CKD amongst SCD patients is shown. In the
model, age remained a significant factor to the develop-
ment of CKD.
Discussion
The haemodynamic changes that occur with chronic an-
aemia, renal hypoxia that results from recurrent vaso-
occlusion and haemolysis-related endothelial dysfunction
can lead to functional and structural changes which may
progress to CKD [8, 10-12]. The results of this study
showed that 39.2 % of SCD participants had CKD. Preva-
lence of CKD in the paediatric population was 31.6 % and
that in the adult population was 68.4 %. Proteinuria and
CKD was more common in HbSS genotype than in HbSC
genotype. CKD is common amongst SCD patients and
prevalence and intensity increases with age.
The prevalence rate of CKD observed in children is
higher than that reported in other studies [1, 26, 27]. In
a recent study conducted in children, a CKD prevalence
Table 1 Baseline characteristics of study population
Variable Hb Genotype Total P-value
SS SC
(n = 142) (n = 52) (n = 194)
Age (years) 20.77 ± 10.52 30.00 ± 13.49 23.25 ± 12.04 0.001
Gender 0.296
Male 66 (46.5) 18 (34.6) 84 (43.3)
Female 76 (53.5) 34 (65.4) 110 (56.7)
Age group n (%) 0.035
<10 24 (16.9) 2 (3.8) 26 (13.4)
10-19. 48 (33.8) 10 (19.2) 58 (29.9)
20-29 46 (32.4) 16 (30.8) 62 (32.0)
30-39 14 (9.9) 14 (26.9) 28 (14.4)
≥40 10 (7.0) 10 (19.2) 20 (10.3)
Blood pressure (mmHg)
SBP 108.65 ± 8.45 113.92 ± 6.46 110.06 ± 8.27 0.005
DBP 65.89 ± 7.67 70.65 ± 8.84 67.16 ± 8.23 0.011
BMI (Kg/m2) 18.48 ± 12.91 19.84 ± 3.59 18.85 ± 11.19 0.599
BMI n (%) 0.002
Underweight 106 (74.6) 20 (38.5) 126 (64.9)
Normal 32 (22.5) 24 (46.2) 56 (28.9)
Overweight 4 (2.8) 8 (15.4) 12 (6.2)
Proteinuria 0.881
Negative 84 (59.2) 34 (65.4) 118 (60.8)
Trace 36 (25.4) 14 (26.9) 50 (25.8)
1+ 8 (5.6) 2 (3.8) 10 (5.2)
2+ 12 (8.5) 2 (3.8) 14 (7.2)
3+ 2 (1.4) 0 (0.0) 2 (1.0)
Serum Creatinine (μmol/l) 46.19 ± 13.39 55.18 ± 12.72 48.60 ± 13.75 0.004
eGFR, mL/min/1.73 m2 136.09 ± 24.70 119.19 ± 16.39 131.56 ± 23.90 0.002
Haematological profile
WBC x 103/mm3 11.83 ± 2.94 9.70 ± 4.31 11.26 ± 3.47 0.007
RBC x106/mm3 2.83 ± 0.77 3.86 ± 1.10 3.11 ± 0.98 0.000
HGB (g/dl) 8.18 ± 1.45 14.87 ± 12.86 9.97 ± 11.61 0.011
HCT (%) 25.53 ± 12.98 28.46 ± 7.53 26.31 ± 19.20 0.508
PLT x 103/mm3 318.14 ± 131.94 209.92 ± 79.58 289.13 ± 129.09 0.331
P <0.05 is significant, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure, BMI = Body Mass Index, eGFR = estimated Glomerular Filtration Rate,
WBC =White Blood Cell, RBC = Red Blood Cell, HGB/Hb = Haemoglobin, HCT = Haematocrit, PLT = Platelet
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that observed in the present study. The prevalence of
CKD observed in the adult population was higher than
that reported in other studies. In a study where an adult
cohort of SCD patients were followed up, a baseline
CKD of 28.6 % was reported [26]. The differences in
prevalence has however been suggested to be due to dif-
ferences in the type of equations used across different
studies [27]. The different population groups used acrossdifferent studies could also account for this difference,
as seen in the present study. As such, prevalence may
differ within different age groups.
The prevalence of CKD in the adult cohort study how-
ever increased to 41.8 % after a five year follow up [26].
This is consistent with the high prevalence as well as the
increase in prevalence with age, as observed in the present
study. Of note, this study adds to evidence from other
studies conducted on renal abnormalities in SCD, that
Table 2 Characteristics of SCD patients with chronic kidney disease
Variable Hb Genotype
SS SC P-value
(n = 58) (n = 18)
Age (years) 25.10 ± 9.73 35.33 ± 14.82 <0.001
Gender
Male 32 (55.2) 4 (22.2) 0.084
Female 26 (44.8) 14 (77.8)
Age group n (%)
<10 2 (3.4) 0 (0.0) 0.373
10-19. 20 (34.5) 2 (11.1)
20-29 22 (37.9) 6 (33.3)
30-39 8 (13.8) 4 (22.2)
≥40 6 (10.3) 6 (33.3)
Blood pressure (mmHg)
SBP 109.21 ± 7.04 115.78 ± 7.45 0.005
DBP 64.93 ± 7.64 74.22 ± 8.69 0.011
BMI (Kg/m2) 17.75 ± 3.32 19.20 ± 4.35 0.599
BMI n (%)
Underweight 36 (62.1) 12 (66.7) 0.018
Normal 22 (37.9) 2 (11.1)
Overweight 0 (0.0) 4 (22.2)
Haematological profile
WBC x 103/mm3 11.43 ± 3.07 8.41 ± 3.82 0.020
RBC x106/mm3 2.93 ± 0.86 4.15 ± 1.02 0.001
HGB (g/dl) 8.35 ± 1.60 10.83 ± 2.56 0.001
HCT (%) 29.74 ± 8.02 29.91 ± 7.83 0.989
PLT x 103/mm3 348.1 ± 140.5 205.9 ± 84.42 0.007
P <0.05 is significant, SBP = Systolic Blood Pressure, DBP = Diastolic Blood
Pressure, BMI = Body Mass Index, eGFR = estimated Glomerular Filtration Rate,
WBC =White Blood Cell, RBC = Red Blood Cell, HGB/Hb = Haemoglobin,
HCT = Haematocrit, PLT = Platelet





≥90 mL/min/1.73 m2 190 (97.9)
60-89 mL/min/1.73 m2 4 (2.1)
CKD, n (%)
Stage 1: eGFR≥ 90 + albuminuria 74 (38.1)
Stage 2: eGFR 60–89 + albuminuria 2 (1.1)
Total CKD, n (%)
Stages (1–2) 76 (39.2)
P <0.05 is significant, eGFR = estimated Glomerular Filtration Rate, CKD = Chronic Ki
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of increase in CKD with age supports the hypothesis that,
sickle cell nephropathy is a progressive condition that be-
gins during childhood [1].
It has been suggested however, that children with
sickle cell anaemia (SCA) develop renal haemodynamic
alterations like renal hyperperfusion and glomerular
hyperfiltration (as observed in the present study), a re-
sult of renal vasodilation associated with chronic an-
aemia. These changes may be followed by glomerular
proteinuria and progressive renal insufficiency [27].
These haemodynamically-mediated changes have been
documented histologically in patients with SCA as glom-
erular hypertrophy [5]. With the evidence discussed
above, we can speculate that anaemia per se, could cause
glomerular damage and our observation of a higher
prevalence of albuminuria and CKD in HbSS disease
(with a usually lower haemoglobin) than in other sick-
ling haemoglobinopathies is in support of this. Much
more needs to be studied on the pathogenesis of glom-
erular damage in SCD.
We observed a significantly lower blood pressure
amongst HbSS participants. Although not significant a
similar study showed a slightly higher DBP in both
males and females with HbSC compared to HbSS [30].
Patients with HbSS disease have a significantly lower
DBP (P <0.001) and slightly lower SBP (P = 0.09) when
compared to healthy controls [31]. Furthermore, com-
pared to normal controls, blood pressure has been
shown to be lower in patients with sickle cell anaemia
(SCA) [32, 33] a more common occurrence amongst
HbSS individuals. Guasch et al., [27] proposed that in a
majority of HbSS patients, systemic blood pressure does
not increase in renal insufficiency when compared to
non-HbSS sickling disorders. The exact mechanism that
mediates this relative resistance to hypertension in pa-
tients with HbSS and renal insufficiency, they say, is not
known [27]. The activation of the Nitric oxide (NO)fied by SCD genotype
Hb Genotype P-
valueSS (n = 142) SC (n = 52)
58 (40.8) 18 (34.6) 0.578
140 (98.6) 50 (96.2) 0.454
2 (1.4) 2 (3.8)
58 (40.8) 16 (30.8) 0.366
0 (0.0) 2 (3.8) 0.097
58 (40.8) 18 (34.6) 0.578
dney Disease. Hb = Haemoglobin
Table 4 Baseline characteristics of SCD patients based on
chronic kidney disease status
Variable CKD STATUS
CKD No CKD P-value
(n = 76) (n = 118)
Age (years) 27.53 ± 11.77 20.49 ± 11.48 0.004
Gender 0.516
Male 36 (47.4) 48 (40.7)
Female 40 (52.6) 70 (59.3)
Age group n (%) 0.099
<10 2 (2.6) 24 (20.3)
10-19. 22 (28.9) 36 (30.5)
20-29 28 (36.8) 34 (28.8)
30-39 12 (15.8) 16 (13.6)
≥40 12 (15.8) 8 (6.8)
Blood pressure
SBP 110.76 ± 7.59 109.61 ± 8.72 0.506
DBP 67.13 ± 8.75 67.19 ± 7.96 0.975
BMI (Kg/m2) 18.04 ± 3.59 19.38 ± 14.09 0.560
BMI n (%) 0.871
Underweight 48 (63.2) 78 (66.1)
Normal 24 (31.6) 32 (27.1)
Overweight 4 (5.3) 8 (6.8)
Haematological profile
WBC x 103/mm3 10.71 ± 3.46 11.62 ± 3.46 0.213
RBC x106/mm3 3.22 ± 1.03 3.03 ± 0.95 0.366
HGB (g/dl) 8.94 ± 2.12 10.63 ± 4.80 0.487
HCT (%) 29.78 ± 9.81 24.08 ± 5.50 0.154
PLT x 103/mm3 314.42 ± 142.26 272.85 ± 118.25 0.122
P <0.05 is significant, CKD = Chronic Kidney Disease, SBP = Systolic Blood
Pressure, DBP = Diastolic Blood Pressure, BMI = Body Mass Index, eGFR =
estimated Glomerular Filtration Rate, WBC =White Blood Cell, RBC = Red Blood
Cell, HGB = Haemoglobin, HCT = Haematocrit, PLT = Platelet
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hypertension in such individuals. In other experiments,
humans with SCA have been shown to excrete a higher
volume of urinary Nitric oxide (NO) metabolites than in
non-anemic control subjects [34], and the peripheralTable 5 Factors associated with chronic kidney disease in SCD
Variable OR (95 % CI) P-value
Age (years) 0.92 (0.87-0.97) 0.001
Hb Genotype 2.11 (0.69-6.45) 0.193
Gender 1.61 (0.64-4.01) 0.310
SBP (mmHg) 0.96 (0.90-1.04) 0.321
DBP (mmHg) 1.01 (0.97-1.13) 0.204
BMI (kg/m2) 1.08 (0.93-1.25) 0.337
OR = odds ratio; CI = Confidence interval, Hb = Haemoglobin, SBP = Systolic
Blood Pressure, DBP = Diastolic Blood Pressure, BMI = Body Mass Indexvessels show a decreased response to blockade of the
NO system [35].
Limitations
Due to limited resources, we were unable to use more sensi-
tive and reliable quantitative methods of detecting protein-
uria. Urine creatinine levels were not determined, although
it would be of interest to perform statistical analysis accord-
ing to Albumin-Creatinine Ratio (ACR) levels. Moreover, a
single urine measurement was used to assess CKD based on
staging criteria. Data on the availability of patients who re-
ceived anti-hypertensive treatment was not available to us.
There is limitation on the generalization of the study find-
ings due to consecutive sampling technique used.
Conclusion
Results from this study suggest that CKD is common in
SCD patients. CKD prevalence and intensity increases
with age in SCD patients and is more prevalent amongst
adults. Proteinuria and CKD was more common in
HbSS genotype than HbSC genotype. With the improve-
ment in care and longevity of SCD patients, the high
prevalence of CKD in SCD is indicative of the fact that
SCD patients may be at risk for the development of pro-
gressive renal insufficiency and later renal failure.
Additional files
Additional file 1: QUESTIONNAIRE.
Abbreviations
BMI: Body Mass Index; CKD-EPI: Chronic kidney disease epidemiology
collaboration; CKD: Chronic kidney disease; eGFR: estimated Glomerular
filtration rate; KDIGO: Kidney Disease Improving Global Outcomes; SCD: Sickle
cell disease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RKDE, DNMO, OC and EAO conceived of the study and participated in its
design and coordination. OC, EAO, JA and LAA were involved in the
recruitment of participants, data collection and analysis of samples. RKDE,
DNMO drafted the manuscript. HA and PA provided analytic and statistical
support. All authors read and approved the final manuscript.
Acknowledgement
Immense gratitude goes to the staff and patients at the Tema General
Hospital, who took part in the study. This research received no grant from
any funding agency in the public, commercial or not-for-profit sectors.
Author details
1Medical Laboratory Division, Department of Medical Laboratory Technology,
UCC, Cape Coast, Ghana. 2Department of Molecular Medicine, School of
Medical Sciences, Kwame Nkrumah University of Science and Technology,
College of Health Sciences, Kumasi, Ghana. 3Sickle Cell Unit, Tema General
Hospital, Tema, Ghana.
Received: 5 December 2014 Accepted: 21 May 2015
Ephraim et al. BMC Nephrology  (2015) 16:75 Page 7 of 7References
1. McPherson Yee M, Jabbar SF, Osunkwo I, Clement L, Lane PA, Eckman JR,
et al. Chronic kidney disease and albuminuria in children with sickle cell
disease. Clin J Am Soc Nephrol. 2011;6(11):2628–33.
2. Powars, Elliot-Mills DD, Chan L, Hiti AL, Opas LM, Johnson C. Chronic renal
failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann
Intern Med. 1991;115:614–20.
3. Ohene-Frempong K, Oduro J, Tetteh H, Nkrumah F. Screening newborns for
sickle cell disease in Ghana. Paediatrics. 2008;121:S120–1.
4. Konotey-Ahulu FID. The Sickle Cell Disease Patient London and Basingstoke:
Macmillan Publsihing Company. 1991.
5. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC.
Prevalence and pathologic features of sickle cell nephropathy and response
to inhibition of angiotensin-converting enzyme. N Engl J Med.
1992;326(14):910–5.
6. Platt RS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al.
Mortality in sickle cell disease. N Engl J Med. 1994;330:1639–44.
7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI,
et al. A new equation to estimate glomerular filtration rate. Ann Intern Med.
2009;150(9):604–12.
8. Serjeant GR, Serjeant BE. Sickle Cell Disease, 3rd ed. edn. Oxford, United
Kingdom: Oxford University Press; 2001.
9. Saborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol.
1999;10(1):187–92.
10. Kadiri S: Chronic kidney disease: Sickle cell nephropathy as a likely cause.
Annals of Ibadan Postgraduate Med 2006;4:7-10.
11. Day TG, Drasar ER, Fulford T, Sharpe CC, Thein SL. Association between
hemolysis and albuminuria in adults with sickle cell anemia. Haematologica.
2012;97(2):201–5.
12. Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E, et al.
Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis
associated feature. Clin J Am Soc Nephrol. 2010;5(5):756–61.
13. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med.
1990;150(3):501–4.
14. Schmitt F, Martinez F, Brillet G, Giatras I, Choukroun G, Girot R, et al. Early
glomerular dysfunction in patients with sickle cell anemia. Am J Kidney Dis.
1998;32(2):208–14.
15. Kirkendall WM, Burton AC, Epstein FH, Freis ED. Recommendations for
human blood pressure determination by sphygmomanometers. Circulation.
1967;36(6):980–8.
16. Adult BMI [http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/
index.html]
17. Gonzalez-Casanova I, Sarmiento OL, Gazmararian JA, Cunningham SA,
Martorell R, Pratt M, et al. Comparing three body mass index classification
systems to assess overweight and obesity in children and adolescents.
Rev Panam Salud Publica. 2013;33(5):349–55.
18. BMI for children and teens [http://www.cdc.gov/healthyweight/assessing/
bmi/childrens_bmi/about_childrens_bmi.html]
19. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management
of Chronic Kidney Disease. Kidney interSuppl. 2013;3(1):1–150.
20. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration
for estimating glomerular filtration rate in infants, children, and adolescents.
Pediatric Clinics of North America. 1987;34(3):571–90.
21. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al.
New equations to estimate GFR in children with CKD. Am Soc Nephrol.
2009;20(3):629–37.
22. Arlet JB, Ribeil JA, Chatellier G, Eladari D, De Seigneux S, Souberbielle JC,
et al. Determination of the best method to estimate glomerular filtration
rate from serum creatinine in adult patients with sickle cell disease: a
prospective observational cohort study. BMC Nephrology. 2012;13:83.
23. Stevens PE, Levin A. Evaluation and management of chronic kidney disease:
synopsis of the kidney disease: improving global outcomes 2012 clinical
practice guideline. Ann Intern Med. 2012;158(11):825–30.
24. Chaiken RL, Eckert-Norton M, Bard M, Banerji MA, Palmisano J, Sachimechi I,
et al. Hyperfiltration in African-American patients with type 2 diabetes.
Cross-sectional and longitudinal data. Diabetes care. 1998;21(12):2129–34.
25. Pruijm M, Wuerzner G, Maillard M, Bovet P, Renaud C, Bochud M, et al.
Glomerular hyperfiltration and increased proximal sodium reabsorption in
subjects with type 2 diabetes or impaired fasting glucose in a population of
the African region. Nephrol Dial Transplant. 2010;25(7):2225–31.26. Gosmanova EO, Zaidi S, Wan JY, Adams-Graves PE. Prevalence and
progression of chronic kidney disease in adult patients with sickle cell
disease. J Investig Med. 2014;62(5):804–7.
27. Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults
with sickle cell hemoglobinopathies: Prevalence and clinical correlates of
progressive renal failure. J Am Soc Nephrol. 2006;17(8):2228–35.
28. Bodas P, Huang A, O'Riordan MA, Sedor JR, Dell KM. The prevalence of
hypertension and abnormal kidney function in children with sickle cell
disease -a cross sectional review. BMC Nephrology. 2013;14:237.
29. Bolarinwa RA, Akinlade KS, Kuti MA, Olawale OO, Akinola NO. Renal disease
in adult Nigerians with sickle cell anemia: a report of prevalence, clinical
features and risk factors. Saudi J Kidney Dis Transpl. 2012;23(1):171–5.
30. Homi J, Homi-Levee L, Gentles S, Thomas P, Serjeant G. Adolescent blood
pressure in a cohort study of sickle cell disease. Arch Intern Med.
1993;153(10):1233–6.
31. Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal
function in homozygous sickle cell disease: observations from a cohort
study. Arch Intern Med. 2007;167(7):701–8.
32. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al.
Pulmonary hypertension as a risk factor for death in patients with sickle cell
disease. N Engl J Med. 2004;350(9):886–95.
33. Jaja SI, Opesanwo O, Mojiminiyi FB, Kehinde MO. Lung function,
haemoglobin and irreversibly sickled cells in sickle cell patients. West Afr J
Med. 2000;19(3):225–9.
34. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric Oxide
Metabolites in Sickle Cell Anemia Patients after Oral Administration of
Hydroxyurea; Hemoglobinopathy. Hematology. 2000;5(4):335–9.
35. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, et al.
Endothelial dysfunction in patients with sickle cell disease is related to
selective impairment of shear stress-mediated vasodilation.
Blood. 2001;97(6):1584–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
